Plain-English translation of NCT07923097 on ClinicalTrials.gov ↗ · Source last updated · How we translate trials
Read our Epilepsy research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Australia
Phase
Safety & dosing
Sponsor
Rapport Therapeutics Inc.
Enrollment target
~60 participants
Started
November 2026
Primary completion
June 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in November 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rapport Medical
Rapport Therapeutics Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.